Featured Research

from universities, journals, and other organizations

Race could be a factor in head, neck cancer survival rates

Date:
June 5, 2014
Source:
University of Missouri-Columbia
Summary:
The national survival rates for African-Americans diagnosed with head and neck cancer have not improved in the last 40 years despite advances in the treatment and management of the disease, researchers have found. The researchers suggest that inherent genetic factors in African-Americans may make some tumors resistant to treatments. However, more research needs to be done on the subject of survival disparity in patients with head and neck cancer.

The national survival rates for African-Americans diagnosed with head and neck cancer have not improved in the last 40 years despite advances in the treatment and management of the disease, University of Missouri School of Medicine researchers have found in a new study.

More than 52,000 men and women in the United States currently are living with head and neck cancer. Using data from the National Cancer Institute's Surveillance, epidemiology and end results (SEER) program, MU researchers under the guidance of Mosharraf Hossain, MD, assistant professor in the MU School of Medicine's Division of Hematology and Oncology and physician with Ellis Fischel Cancer Center in Columbia, Mo., studied the survival trend of five ethnic groups over the last 40 years. The researchers found that despite advances in treatment options, the prognosis for African-Americans with head and neck cancer has not improved.

"This study shows that we've made good progress in treating head and neck cancer over the last 37 years, and survival has dramatically improved," said Shahzad Raza, MD, a post-doctoral fellow in the MU School of Medicine's Division of Hematology and Oncology and lead investigator of the study. "However, we found no change in the survival or prognosis for African-Americans in the last four decades."

By analyzing data collected from 1973 to 2010 on 247,310 head and neck cancer patients nationwide, the researchers found that the incidence of head and neck cancer was higher in African-Americans than in Caucasians, Hispanics, Asians and Pacific Islanders, or Asian-Indian and Alaskan natives. All of these ethnic groups except African-Americans showed improved five-year survival rates over a 40-year period. African-Americans had a significantly decreased five-year overall survival rate of 41.8 percent, compared with 60.8 percent survival for Caucasians, 59.3 percent survival for Hispanics, 62 percent survival for Asians and Pacific Islanders, and 50.2 percent survival for Asian-Indian and Alaskan natives.

"One commonly held theory is that socioeconomic status, access to health care and the stage in which the cancer is diagnosed all play a major role in the survival rates of African-Americans with head and neck cancer," Raza said. "However, these factors are not completely accurate predictors of a patient's prognosis."

Raza said the treatment for head and neck cancer depends on the location of the tumor, the stage of the cancer, and the patient's age and overall health. Treatments can include surgery, radiation therapy, chemotherapy, targeted therapy or a combination of treatment options.

The researchers suggest that inherent genetic factors in African-Americans may make some tumors resistant to treatments. However, more research needs to be done on the subject of survival disparity in patients with head and neck cancer. "This research shows there is an urgent need for a national trial on head and neck cancer within the African-American community to evaluate new forms of treatment and biogenetic markers to learn why this ethnic group has decreased survival rates," Raza said.


Story Source:

The above story is based on materials provided by University of Missouri-Columbia. Note: Materials may be edited for content and length.


Cite This Page:

University of Missouri-Columbia. "Race could be a factor in head, neck cancer survival rates." ScienceDaily. ScienceDaily, 5 June 2014. <www.sciencedaily.com/releases/2014/06/140605113705.htm>.
University of Missouri-Columbia. (2014, June 5). Race could be a factor in head, neck cancer survival rates. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2014/06/140605113705.htm
University of Missouri-Columbia. "Race could be a factor in head, neck cancer survival rates." ScienceDaily. www.sciencedaily.com/releases/2014/06/140605113705.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins